massarray iplex genotyping assay (agena bioscience)
agena bioscience is a verified supplier 
agena bioscience manufactures this product 
90
Structured Review
agena bioscience
massarray iplex genotyping assay
Massarray Iplex Genotyping Assay, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+iplex+genotyping/massarray+iplex+genotyping/pmc11505229-82-1-6
Average 90 stars, based on 1 article reviews
Massarray Iplex Genotyping Assay, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+iplex+genotyping/massarray+iplex+genotyping/pmc11505229-82-1-6
Average 90 stars, based on 1 article reviews
massarray iplex genotyping assay - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Multiplex Assay:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and tumor suppressor genes (Panel Lungcarta© - MassARRAY iPLEX genotyping technology (Agena Bioscience, San Diego, USA), as previously described [7]. .. For the adenocarcinomas cohort, routine molecular analysis for EGFR, KRAS, BRAF, HER2, and PI3KCA mutations were run using the Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung Article Snippet: For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and tumor suppressor genes (Panel Lungcarta© - MassARRAY iPLEX genotyping technology (Agena Bioscience, San Diego, USA), as previously described [ ]. .. For the adenocarcinomas cohort, routine molecular analysis for EGFR, KRAS, BRAF, HER2, and PI3KCA mutations were run using the Polymerase Chain Reaction:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and tumor suppressor genes (Panel Lungcarta© - MassARRAY iPLEX genotyping technology (Agena Bioscience, San Diego, USA), as previously described [7]. .. For the adenocarcinomas cohort, routine molecular analysis for EGFR, KRAS, BRAF, HER2, and PI3KCA mutations were run using the Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung Article Snippet: For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and tumor suppressor genes (Panel Lungcarta© - MassARRAY iPLEX genotyping technology (Agena Bioscience, San Diego, USA), as previously described [ ]. .. For the adenocarcinomas cohort, routine molecular analysis for EGFR, KRAS, BRAF, HER2, and PI3KCA mutations were run using the other:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung Article Snippet: For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and |
